Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging
暂无分享,去创建一个
Isaiah Norton | Nathalie Y. R. Agar | Sandro Santagata | Mark A. Marchionni | Jeffrey N. Agar | Santosh Kesari | I. Norton | S. Kesari | Maritza C. Ebling | S. Santagata | N. Agar | J. Alberta | C. Stiles | J. Agar | D. Stuart | C. Sauvageot | Xiaohui Liu | M. Easterling | Charles D. Stiles | K. Kellersberger | Xiaohui Liu | M. Marchionni | Jennifer L. Ide | Michael L. Easterling | Lan Y. Wang | Erin Davis | Claire M. Sauvageot | Katherine A. Kellersberger | Darrin D. Stuart | John Alberta | E. Davis
[1] W. Löscher,et al. The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses , 2007, Clinical Cancer Research.
[2] Maxime Culot,et al. Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.
[3] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[4] G. V. Van Berkel,et al. Comparison of drug distribution images from whole-body thin tissue sections obtained using desorption electrospray ionization tandem mass spectrometry and autoradiography. , 2008, Analytical chemistry.
[5] Stevan W. Djuric,et al. F1000Prime recommendation of Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010 .
[6] S. Liddelow,et al. Transporters of the blood-brain and blood-CSF interfaces in development and in the adult. , 2013, Molecular aspects of medicine.
[7] Thomas Ludwig,et al. Glioblastoma cells release factors that disrupt blood-brain barrier features , 2004, Acta Neuropathologica.
[8] Francesco Hofmann,et al. PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. , 2010, Neuro-oncology.
[9] M. Berger,et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.
[10] L. Signor,et al. Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry. , 2007, Journal of mass spectrometry : JMS.
[11] C. García-echeverría. Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways , 2008, Purinergic Signalling.
[12] Alain Schweitzer,et al. Autoradiography, MALDI-MS, and SIMS-MS Imaging in Pharmaceutical Discovery and Development , 2010, The AAPS Journal.
[13] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.
[14] P. Jeffrey,et al. Assessment of the blood–brain barrier in CNS drug discovery , 2010, Neurobiology of Disease.
[15] J. Panetta,et al. Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 , 2007, Clinical Cancer Research.
[16] Alfred L. Nuttall,et al. Techniques for the observation and measurement of red blood cell velocity in vessels of the guinea pig cochlea , 1987, Hearing Research.
[17] G. Reifenberger,et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. , 2008, The Journal of clinical investigation.
[18] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[19] M. Chamberlain. Anticancer therapies and CNS relapse: overcoming blood–brain and blood–cerebrospinal fluid barrier impermeability , 2010, Expert review of neurotherapeutics.
[20] K. Wong,et al. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. , 2009, Recent patents on anti-cancer drug discovery.
[21] J. Dufour,et al. PI(3)K/PTEN/AKT pathway. , 2011, Journal of hepatology.
[22] Mitsutoshi Setou,et al. Imaging Mass Spectrometry for Visualization of Drug and Endogenous Metabolite Distribution: Toward In Situ Pharmacometabolomes , 2010, Journal of Neuroimmune Pharmacology.
[23] P. Caravatti,et al. The ‘infinity cell’: A new trapped‐ion cell with radiofrequency covered trapping electrodes for fourier transform ion cyclotron resonance mass spectrometry , 1991 .
[24] F. Loop,et al. Cerebral microembolism during cardiopulmonary bypass. Retinal microvascular studies in vivo with fluorescein angiography. , 1988, The Journal of thoracic and cardiovascular surgery.
[25] W. Sellers,et al. Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.
[26] N. M. Karabacak,et al. Transformative effects of higher magnetic field in Fourier transform ion cyclotron resonance mass spectrometry , 2010, Journal of the American Society for Mass Spectrometry.
[27] Marketa Zvelebil,et al. Phosphoinositide 3-kinase signalling--which way to target? , 2003, Trends in pharmacological sciences.
[28] W. Pardridge,et al. Blood-brain barrier delivery. , 2007, Drug discovery today.
[29] Pengyu Hong,et al. A hierarchical algorithm for calculating the isotopic fine structures of molecules , 2008, Journal of the American Society for Mass Spectrometry.
[30] T. Davis,et al. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.
[31] Mehrdad Hamidi,et al. Brain drug targeting: a computational approach for overcoming blood-brain barrier. , 2009, Drug discovery today.
[32] C. Prakash,et al. METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS , 2006, Drug Metabolism and Disposition.
[33] Masami Niwa,et al. Permeability Studies on In Vitro Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology , 2005, Cellular and Molecular Neurobiology.
[34] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[35] Brendan Prideaux,et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. , 2011, Analytical chemistry.
[36] Ming-Sound Tsao,et al. A review of erlotinib and its clinical use , 2006, Expert opinion on pharmacotherapy.
[37] E. Solon,et al. Whole-body autoradiography in drug discovery. , 2002, Current drug metabolism.
[38] R. McLendon,et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. , 1997, Cancer research.